

# Alexander U. Brandt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7069845/publications.pdf>

Version: 2024-02-01

149  
papers

6,829  
citations

71102

41  
h-index

71685

76  
g-index

155  
all docs

155  
docs citations

155  
times ranked

5529  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impaired motion perception is associated with functional and structural visual pathway damage in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2022, 28, 757-767.	3.0	3
2	Modular deep neural networks for automatic quality control of retinal optical coherence tomography scans. <i>Computers in Biology and Medicine</i> , 2022, 141, 104822.	7.0	10
3	Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 188-195.	1.9	13
4	Nicolau Syndrome After Glatiramer Acetate Injection in Close Proximity to Administration of SARS-CoV-2 mRNA Vaccine. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, e1112.	6.0	2
5	Proposal for Post Hoc Quality Control in Instrumented Motion Analysis Using Markerless Motion Capture: Development and Usability Study. <i>JMIR Human Factors</i> , 2022, 9, e26825.	2.0	2
6	Choroid Plexus Volume in Multiple Sclerosis vs Neuromyelitis Optica Spectrum Disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	6.0	32
7	Diagnostic efficacy of the magnetic resonance T1w/T2w ratio for the middle cerebellar peduncle in multiple system atrophy and spinocerebellar ataxia: A preliminary study. <i>PLoS ONE</i> , 2022, 17, e0267024.	2.5	1
8	Intraretinal Layer Segmentation Using Cascaded Compressed U-Nets. <i>Journal of Imaging</i> , 2022, 8, 139.	3.0	7
9	Longitudinal Retinal Changes in <scp>MOGAD</scp>. <i>Annals of Neurology</i> , 2022, 92, 476-485.	5.3	20
10	Magnetic resonance T1w/T2w ratio in the middle cerebellar peduncle might be a sensitive biomarker for multiple system atrophy. <i>European Radiology</i> , 2021, 31, 4277-4284.	4.5	8
11	Longitudinal analysis of primary and secondary factors related to fatigue in multiple sclerosis. <i>Acta Neurologica Belgica</i> , 2021, 121, 271-274.	1.1	1
12	Neurochemical Differences in Spinocerebellar Ataxia Type 14 and 1. <i>Cerebellum</i> , 2021, 20, 169-178.	2.5	0
13	A novel investigation method for axonal damage in neuromyelitis optica spectrum disorder: In vivo corneal confocal microscopy. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732199806.	1.0	1
14	Epigallocatechin Gallate in Progressive MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	12
15	Cultural bias in motor function patterns: Potential relevance for predictive, preventive, and personalized medicine. <i>EPMA Journal</i> , 2021, 12, 91-101.	6.1	4
16	Epigallocatechin Gallate in Relapsing-Remitting Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	16
17	Foveal changes in aquaporinâ€4 antibody seropositive neuromyelitis optica spectrum disorder are independent of optic neuritis and not overtly progressive. <i>European Journal of Neurology</i> , 2021, 28, 2280-2293.	3.3	14
18	Spinocerebellar ataxia type 14: refining clinicogenetic diagnosis in a rare adultâ€onset disorder. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 774-789.	3.7	13

#	ARTICLE	IF	CITATIONS
19	Longitudinal analysis of T1w/T2w ratio in patients with multiple sclerosis from first clinical presentation. <i>Multiple Sclerosis Journal</i> , 2021, 27, 2180-2190.	3.0	12
20	APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies. <i>Neurology</i> , 2021, 97, 68-79.	1.1	96
21	Retinal Thickness Analysis in Progressive Multiple Sclerosis Patients Treated With Epigallocatechin Gallate: Optical Coherence Tomography Results From the SUPREMES Study. <i>Frontiers in Neurology</i> , 2021, 12, 615790.	2.4	7
22	AQP4-IgG autoimmunity in Japan and Germany: Differences in clinical profiles and prognosis in seropositive neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110068.	1.0	6
23	Artificial intelligence extension of the OSCAR criteria. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1528-1542.	3.7	33
24	Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. <i>Journal of Neuroinflammation</i> , 2021, 18, 105.	7.2	44
25	Association of a Marker of N-Acetylglucosamine With Progressive Multiple Sclerosis and Neurodegeneration. <i>JAMA Neurology</i> , 2021, 78, 842.	9.0	15
26	Cognitive Impairment in Multiple System Atrophy Is Related to White Matter Damage Detected by the T1-Weighted/T2-Weighted Ratio. <i>European Neurology</i> , 2021, 84, 435-443.	1.4	5
27	Increased Serum Neurofilament Light and Thin Ganglion Cell Inner Plexiform Layer Are Additive Risk Factors for Disease Activity in Early Multiple Sclerosis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	6.0	29
28	Retinal Optical Coherence Tomography in Neuromyelitis Optica. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	6.0	47
29	Lateral geniculate nucleus volume changes after optic neuritis in neuromyelitis optica: A longitudinal study. <i>NeuroImage: Clinical</i> , 2021, 30, 102608.	2.7	9
30	Frequency of autoimmune disorders and autoantibodies in European patients with neuromyelitis optica spectrum disorders. <i>Acta Neurologica Belgica</i> , 2020, 120, 223-225.	1.1	11
31	Instrumental Assessment of Stepping in Place Captures Clinically Relevant Motor Symptoms of Parkinson's Disease. <i>Sensors</i> , 2020, 20, 5465.	3.8	8
32	N-acetylglucosamine drives myelination by triggering oligodendrocyte precursor cell differentiation. <i>Journal of Biological Chemistry</i> , 2020, 295, 17413-17424.	3.4	29
33	Blunted neural and psychological stress processing predicts future grey matter atrophy in multiple sclerosis. <i>Neurobiology of Stress</i> , 2020, 13, 100244.	4.0	10
34	Visual system damage and network maladaptation are associated with cognitive performance in neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102406.	2.0	9
35	Functionally Relevant Maculopathy and Optic Atrophy in Spinocerebellar Ataxia Type 1. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 502-508.	1.5	7
36	Ventral posterior nucleus volume is associated with neuropathic pain intensity in neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102579.	2.0	14

#	ARTICLE	IF	CITATIONS
37	Differences in Advanced Magnetic Resonance Imaging in MOG-IgG and AQP4-IgG Seropositive Neuromyelitis Optica Spectrum Disorders: A Comparative Study. <i>Frontiers in Neurology</i> , 2020, 11, 499910.	2.4	14
38	Altered Coupling of Psychological Relaxation and Regional Volume of Brain Reward Areas in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2020, 11, 568850.	2.4	3
39	Effect of vitamin D supplementation on N-glycan branching and cellular immunophenotypes in MS. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1628-1641.	3.7	3
40	Sex differences in brain atrophy in multiple sclerosis. <i>Biology of Sex Differences</i> , 2020, 11, 49.	4.1	51
41	Quantitative Multi-Parameter Mapping Optimized for the Clinical Routine. <i>Frontiers in Neuroscience</i> , 2020, 14, 611194.	2.8	19
42	Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO). <i>BMJ Open</i> , 2020, 10, e035397.	1.9	10
43	Transcriptomics and proteomics reveal a cooperation between interferon and T-helper 17 cells in neuromyelitis optica. <i>Nature Communications</i> , 2020, 11, 2856.	12.8	50
44	SynergyNet: A Fusion Framework for Multiple Sclerosis Brain MRI Segmentation with Local Refinement. , 2020, , .		8
45	Vitamin D and Disease Severity in Multiple Sclerosisâ€”Baseline Data From the Randomized Controlled Trial (EVIDIMS). <i>Frontiers in Neurology</i> , 2020, 11, 129.	2.4	15
46	Fingolimod after a first unilateral episode of acute optic neuritis (MOVING) â€” preliminary results from a randomized, rater-blind, active-controlled, phase 2 trial. <i>BMC Neurology</i> , 2020, 20, 75.	1.8	10
47	Investigation of Visual System Involvement in Spinocerebellar Ataxia Type 14. <i>Cerebellum</i> , 2020, 19, 469-482.	2.5	3
48	Altered fovea in AQP4-IgGâ€”seropositive neuromyelitis optica spectrum disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	50
49	Optic Nerve Head Volumetry by Optical Coherence Tomography in Papilledema Related to Idiopathic Intracranial Hypertension. <i>Translational Vision Science and Technology</i> , 2020, 9, 24.	2.2	10
50	Diagnostic procedures in suspected attacks in patients with neuromyelitis optica spectrum disorders: Results of an international survey. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 41, 102027.	2.0	11
51	Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders. <i>Neurology</i> , 2020, 94, e407-e418.	1.1	36
52	Prodromal headache in MOG-antibody positive optic neuritis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 40, 101965.	2.0	41
53	Association Between Fatigue and Motor Exertion in Patients With Multiple Sclerosisâ€”a Prospective Study. <i>Frontiers in Neurology</i> , 2020, 11, 208.	2.4	18
54	Optic chiasm measurements may be useful markers of anterior optic pathway degeneration in neuromyelitis optica spectrum disorders. <i>European Radiology</i> , 2020, 30, 5048-5058.	4.5	9

#	ARTICLE	IF	CITATIONS
55	Protective effects of 4-aminopyridine in experimental optic neuritis and multiple sclerosis. <i>Brain</i> , 2020, 143, 1127-1142.	7.6	29
56	Evaluation of the "ring sign"™ and the "core sign"™ as a magnetic resonance imaging marker of disease activity and progression in clinically isolated syndrome and early multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020, 6, 205521732091548.	1.0	25
57	Cortical topological network changes following optic neuritis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e687.	6.0	8
58	Considerations for Mean Upper Cervical Cord Area Implementation in a Longitudinal MRI Setting: Methods, Interrater Reliability, and MRI Quality Control. <i>American Journal of Neuroradiology</i> , 2020, 41, 343-350.	2.4	7
59	Transdiagnostic hippocampal damage patterns in neuroimmunological disorders. <i>NeuroImage: Clinical</i> , 2020, 28, 102515.	2.7	11
60	High-dose vitamin D supplementation in multiple sclerosis " results from the randomized EVIDIMS (efficacy of vitamin D supplementation in multiple sclerosis) trial. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020, 6, 205521732090347.	1.0	27
61	The APOSTEL Recommendations. , 2020, , 33-39.		0
62	Author response: Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders. <i>Neurology</i> , 2020, 95, 610-610.	1.1	0
63	Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study. <i>Journal of Neuroinflammation</i> , 2019, 16, 154.	7.2	61
64	Imaging markers of disability in aquaporin-4 immunoglobulin G seropositive neuromyelitis optica: a graph theory study. <i>Brain Communications</i> , 2019, 1, fcz026.	3.3	15
65	Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731987158.	1.0	34
66	Intrathecal IgM production is a strong risk factor for early conversion to multiple sclerosis. <i>Neurology</i> , 2019, 93, e1439-e1451.	1.1	43
67	Uncovering convolutional neural network decisions for diagnosing multiple sclerosis on conventional MRI using layer-wise relevance propagation. <i>NeuroImage: Clinical</i> , 2019, 24, 102003.	2.7	93
68	Quantitative grip force assessment of muscular weakness in chronic inflammatory demyelinating polyneuropathy. <i>BMC Neurology</i> , 2019, 19, 118.	1.8	1
69	Cognitive Impairment in Neuromyelitis Optica Spectrum Disorders: A Review of Clinical and Neuroradiological Features. <i>Frontiers in Neurology</i> , 2019, 10, 608.	2.4	42
70	Attack-related damage of thalamic nuclei in neuromyelitis optica spectrum disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1156-1164.	1.9	20
71	Neural mechanisms of perceptual decision-making and their link to neuropsychiatric symptoms in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 33, 139-145.	2.0	4
72	Damage of the lateral geniculate nucleus in MS. <i>Neurology</i> , 2019, 92, e2240-e2249.	1.1	29

#	ARTICLE	IF	CITATIONS
73	Standardization of T1w/T2w Ratio Improves Detection of Tissue Damage in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2019, 10, 334.	2.4	31
74	Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: An international study. <i>Annals of Neurology</i> , 2019, 85, 618-629.	5.3	104
75	Contactless recording of sleep apnea and periodic leg movements by nocturnal 3-D-video and subsequent visual perceptive computing. <i>Scientific Reports</i> , 2019, 9, 16812.	3.3	15
76	Normative Data and Minimally Detectable Change for Inner Retinal Layer Thicknesses Using a Semi-automated OCT Image Segmentation Pipeline. <i>Frontiers in Neurology</i> , 2019, 10, 1117.	2.4	36
77	Novel uses of retinal imaging with optical coherence tomography in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 31-43.	2.8	44
78	Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1926-1936.	3.0	47
79	Automatic quality evaluation as assessment standard for optical coherence tomography. , 2019, , .		2
80	Optical coherence tomography in neuromyelitis optica spectrum disorders: potential advantages for individualized monitoring of progression and therapy. <i>EPMA Journal</i> , 2018, 9, 21-33.	6.1	75
81	Association of Retinal Ganglion Cell Layer Thickness With Future Disease Activity in Patients With Clinically Isolated Syndrome. <i>JAMA Neurology</i> , 2018, 75, 1071.	9.0	72
82	Anatomical Wiring and Functional Networking Changes in the Visual System Following Optic Neuritis. <i>JAMA Neurology</i> , 2018, 75, 287.	9.0	39
83	Safety and preliminary efficacy of deep transcranial magnetic stimulation in MS-related fatigue. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e423.	6.0	52
84	Association of Visual Impairment in Neuromyelitis Optica Spectrum Disorder With Visual Network Reorganization. <i>JAMA Neurology</i> , 2018, 75, 296.	9.0	34
85	Frequent retinal ganglion cell damage after acute optic neuritis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 22, 141-147.	2.0	30
86	Multicenter reliability of semiautomatic retinal layer segmentation using OCT. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e449.	6.0	76
87	Brain activity, regional gray matter loss, and decision-making in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1163-1173.	3.0	21
88	Self-perception and determinants of color vision in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2018, 125, 145-152.	2.8	8
89	The International Multiple Sclerosis Visual System Consortium: Advancing Visual System Research in Multiple Sclerosis. <i>Journal of Neuro-Ophthalmology</i> , 2018, 38, 494-501.	0.8	15
90	MRI Markers and Functional Performance in Patients With CIS and MS: A Cross-Sectional Study. <i>Frontiers in Neurology</i> , 2018, 9, 718.	2.4	14

#	ARTICLE	IF	CITATIONS
91	Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018, 4, 205521731879668.	1.0	40
92	Temporal visual resolution and disease severity in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e492.	6.0	15
93	Comparison of probabilistic tractography and tract-based spatial statistics for assessing optic radiation damage in patients with autoimmune inflammatory disorders of the central nervous system. <i>NeuroImage: Clinical</i> , 2018, 19, 538-550.	2.7	40
94	Retinal ganglion cell loss in neuromyelitis optica: a longitudinal study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 1259-1265.	1.9	100
95	MRI-Based Methods for Spinal Cord Atrophy Evaluation: A Comparison of Cervical Cord Cross-Sectional Area, Cervical Cord Volume, and Full Spinal Cord Volume in Patients with Aquaporin-4 Antibody Seropositive Neuromyelitis Optica Spectrum Disorders. <i>American Journal of Neuroradiology</i> , 2018, 39, 1362-1368.	2.4	13
96	Optical coherence tomography in acute optic neuritis: A population-based study. <i>Acta Neurologica Scandinavica</i> , 2018, 138, 566-573.	2.1	44
97	Active contour method for ILM segmentation in ONH volume scans in retinal OCT. <i>Biomedical Optics Express</i> , 2018, 9, 6497.	2.9	11
98	Subjective and objective assessment of physical activity in multiple sclerosis and their relation to health-related quality of life. <i>BMC Neurology</i> , 2017, 17, 10.	1.8	18
99	Severe structural and functional visual system damage leads to profound loss of vision-related quality of life in patients with neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 11, 45-50.	2.0	89
100	Microstructural visual system changes in AQP4-antibody seropositive NMOSD. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e334.	6.0	128
101	Monitoring the Course of MS With Optical Coherence Tomography. <i>Current Treatment Options in Neurology</i> , 2017, 19, 15.	1.8	40
102	Contribution of blood vessels to retinal nerve fiber layer thickness in NMOSD. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e338.	6.0	19
103	Patient perspectives on neuromyelitis optica spectrum disorders: Data from the PatientsLikeMe online community. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 17, 116-122.	2.0	43
104	Synergistic Strategy for Multicolor Two-photon Microscopy: Application to the Analysis of Germinal Center Reactions In Vivo. <i>Scientific Reports</i> , 2017, 7, 7101.	3.3	48
105	Optical coherence tomography for the diagnosis and monitoring of idiopathic intracranial hypertension. <i>Journal of Neurology</i> , 2017, 264, 1370-1380.	3.6	55
106	Diffusion tensor imaging for multilevel assessment of the visual pathway: possibilities for personalized outcome prediction in autoimmune disorders of the central nervous system. <i>EPMA Journal</i> , 2017, 8, 279-294.	6.1	35
107	Patients with multiple sclerosis demonstrate reduced subbasal corneal nerve fibre density. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1847-1853.	3.0	65
108	CuBe: parametric modeling of 3D foveal shape using cubic B-splines. <i>Biomedical Optics Express</i> , 2017, 8, 4181.	2.9	16

#	ARTICLE	IF	CITATIONS
109	Epstein-Barr virus antibodies in serum and DNA load in saliva are not associated with radiological or clinical disease activity in patients with early multiple sclerosis. <i>PLoS ONE</i> , 2017, 12, e0175279.	2.5	29
110	Maximum walking speed in multiple sclerosis assessed with visual perceptive computing. <i>PLoS ONE</i> , 2017, 12, e0189281.	2.5	29
111	Longitudinal Intravital Imaging of the Retina Reveals Long-term Dynamics of Immune Infiltration and Its Effects on the Glial Network in Experimental Autoimmune Uveoretinitis, without Evident Signs of Neuronal Dysfunction in the Ganglion Cell Layer. <i>Frontiers in Immunology</i> , 2016, 7, 642.	4.8	20
112	RETINAL LESION EVOLUTION IN SUSAC SYNDROME. <i>Retina</i> , 2016, 36, 366-374.	1.7	25
113	The APOSTEL recommendations for reporting quantitative optical coherence tomography studies. <i>Neurology</i> , 2016, 86, 2303-2309.	1.1	331
114	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. <i>Journal of Neuroinflammation</i> , 2016, 13, 279.	7.2	351
115	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. <i>Journal of Neuroinflammation</i> , 2016, 13, 280.	7.2	686
116	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. <i>Journal of Neuroinflammation</i> , 2016, 13, 282.	7.2	217
117	The APOSTEL recommendations for reporting quantitative optical coherence tomography studies. <i>Neurology</i> , 2016, 87, 1960-1960.	1.1	9
118	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome. <i>Journal of Neuroinflammation</i> , 2016, 13, 281.	7.2	202
119	Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e286.	6.0	85
120	Visual dysfunction, but not retinal thinning, following anti-NMDA receptor encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e198.	6.0	21
121	Accuracy and repeatability of two methods of gait analysis "GaitRite" and Mobility Lab" in subjects with cerebellar ataxia. <i>Gait and Posture</i> , 2016, 48, 194-201.	1.4	59
122	Normal volumes and microstructural integrity of deep gray matter structures in AQP4+ NMOSD. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e229.	6.0	47
123	Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. <i>Lancet Neurology</i> , The, 2016, 15, 574-584.	10.2	266
124	Validity of visual perceptive computing for static posturography in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1596-1606.	3.0	39
125	Afferent Visual Pathway Affection in Patients with PMP22 Deletion-Related Hereditary Neuropathy with Liability to Pressure Palsies. <i>PLoS ONE</i> , 2016, 11, e0164617.	2.5	6
126	Accuracy and Reliability of the Kinect Version 2 for Clinical Measurement of Motor Function. <i>PLoS ONE</i> , 2016, 11, e0166532.	2.5	183



#	ARTICLE	IF	CITATIONS
127	Quantitative motor assessment of muscular weakness in myasthenia gravis: a pilot study. BMC Neurology, 2015, 15, 265.	1.8	8
128	Reliability of Intra-Retinal Layer Thickness Estimates. PLoS ONE, 2015, 10, e0137316.	2.5	75
129	Optic radiation damage in multiple sclerosis is associated with visual dysfunction and retinal thinning – an ultrahigh-field MR pilot study. European Radiology, 2015, 25, 122-131.	4.5	84
130	Cerebellar neurochemical alterations in spinocerebellar ataxia type 14 appear to include glutathione deficiency. Journal of Neurology, 2015, 262, 1927-1935.	3.6	13
131	Retinal pathology in idiopathic moyamoya angiopathy detected by optical coherence tomography. Neurology, 2015, 85, 521-527.	1.1	24
132	Optical coherence tomography for retinal imaging in multiple sclerosis. Degenerative Neurological and Neuromuscular Disease, 2014, 4, 153.	1.3	18
133	Dynamic formation of macular microcysts independent of vitreous traction changes. Neurology, 2014, 83, 73-77.	1.1	47
134	Reply: Photoreceptor layer thinning is not specific for Parkinson's disease. Movement Disorders, 2014, 29, 1332-1332.	3.9	0
135	Metabolic Evidence for Cerebral Neurodegeneration in Spinocerebellar Ataxia Type 1. Cerebellum, 2014, 13, 199-206.	2.5	14
136	Relations of low contrast visual acuity, quality of life and multiple sclerosis functional composite: a cross-sectional analysis. BMC Neurology, 2014, 14, 31.	1.8	46
137	Retinal nerve fibre layer thickness correlates with brain white matter damage in multiple sclerosis: A combined optical coherence tomography and diffusion tensor imaging study. Multiple Sclerosis Journal, 2014, 20, 1904-1907.	3.0	36
138	Reply to: Photoreceptor layer thinning in Parkinsonian syndromes. Movement Disorders, 2014, 29, 1223-1224.	3.9	2
139	Using perceptive computing in multiple sclerosis - the Short Maximum Speed Walk test. Journal of NeuroEngineering and Rehabilitation, 2014, 11, 89.	4.6	47
140	Photoreceptor layer thinning in idiopathic Parkinson's disease. Movement Disorders, 2014, 29, 1163-1170.	3.9	84
141	Low contrast visual acuity testing is associated with cognitive performance in multiple sclerosis: a cross-sectional pilot study. BMC Neurology, 2013, 13, 167.	1.8	37
142	Optic Neuritis Is Associated with Inner Nuclear Layer Thickening and Microcystic Macular Edema Independently of Multiple Sclerosis. PLoS ONE, 2013, 8, e71145.	2.5	102
143	Optical Coherence Tomography Reveals Distinct Patterns of Retinal Damage in Neuromyelitis Optica and Multiple Sclerosis. PLoS ONE, 2013, 8, e66151.	2.5	162
144	Retinal Damage in Multiple Sclerosis Disease Subtypes Measured by High-Resolution Optical Coherence Tomography. Multiple Sclerosis International, 2012, 2012, 1-10.	0.8	111

#	ARTICLE	IF	CITATIONS
145	Dynamics of saccade parameters in multiple sclerosis patients with fatigue. Journal of Neurology, 2012, 259, 2656-2663.	3.6	48
146	Optic Nerve Head Quantification in Idiopathic Intracranial Hypertension by Spectral Domain OCT. PLoS ONE, 2012, 7, e36965.	2.5	68
147	Association of Retinal and Macular Damage with Brain Atrophy in Multiple Sclerosis. PLoS ONE, 2011, 6, e18132.	2.5	127
148	Temporal Retinal Nerve Fiber Loss in Patients with Spinocerebellar Ataxia Type 1. PLoS ONE, 2011, 6, e23024.	2.5	57
149	Patterns of retinal nerve fiber layer loss in multiple sclerosis patients with or without optic neuritis and glaucoma patients. Clinical Neurology and Neurosurgery, 2010, 112, 647-652.	1.4	107